BIIB
HEALTHCAREBiogen Inc
$190.68+1.55 (+0.82%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BIIB Today?
No stock-specific AI insight has been generated for BIIB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$118.05$202.41
$190.68
Fundamentals
Market Cap$28.2B
P/E Ratio20.5
EPS$9.31
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume743K
Avg Volume (10D)—
Shares Outstanding147.6M
BIIB News
37 articles- Biogen Inc. stock (US09062X1037): Q1 earnings beat but guidance cut weighs on sentimentAD HOC NEWS·May 9, 2026
- NULLMoomoo·May 9, 2026
- Biogen Stock Gains Despite Extended FDA Review For Alzheimer's TherapyBenzinga·May 8, 2026
- Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapyBioSpace·May 8, 2026
- FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extendedBiopharmadive·May 8, 2026
- GRIMES & Co WEALTH MANAGEMENT LLC Reduces Position in Bristol Myers Squibb Company $BMYMarketBeat·May 8, 2026
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s DiseaseBiogen·May 8, 2026
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s DiseaseGlobeNewswire Inc.·May 8, 2026
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's DiseaseYahoo Finance·May 8, 2026
- Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600Quantisnow·May 7, 2026
- Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab RealityYahoo Finance·May 5, 2026
- Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, TalentYahoo Finance·May 5, 2026
- Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial OperationsYahoo Finance·May 4, 2026
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookBiopharmadive·May 1, 2026
- Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...Yahoo Finance·Apr 30, 2026
- Why Biogen Stock Was a Winner on WednesdayMotley Fool·Apr 30, 2026
- Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price RallyYahoo Finance·Apr 29, 2026
- Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood OutYahoo Finance·Apr 29, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- Biogen Inc. Q1 2026 Earnings Call SummaryMoby·Apr 29, 2026
- Biogen Q1 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A CostsYahoo Finance·Apr 29, 2026
- Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key MetricsYahoo Finance·Apr 29, 2026
- Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 29, 2026
- Biogen shares rise after Q1 beat; full-year profit outlook slashedYahoo Finance·Apr 29, 2026
- Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 SalesYahoo Finance·Apr 29, 2026
- This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?The Motley Fool·Apr 16, 2026
- Administrator Loeffler Applauds SBIR-STTR ReauthorizationGlobeNewswire Inc.·Apr 13, 2026
- Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034GlobeNewswire Inc.·Apr 13, 2026
- Biogen Taps Alloy Platform To Push Antisense Drug Pipeline ForwardBenzinga·Apr 7, 2026
- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightGlobeNewswire Inc.·Apr 6, 2026
- Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers BankruptcyBenzinga·Apr 3, 2026
- Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsightGlobeNewswire Inc.·Apr 1, 2026
- Trump Signals Iran Exit, S&P 500 Heads For Worst Month Since September 2022: What's Moving The Market On Tuesday?Benzinga·Mar 31, 2026
- Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis DealBenzinga·Mar 31, 2026
- Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular AtrophyBenzinga·Mar 30, 2026
- Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease ActivityGlobeNewswire Inc.·Mar 28, 2026
All 37 articles loaded
Price Data
Open$189.13
Previous Close$189.13
Day High$191.17
Day Low$188.30
52 Week High$202.41
52 Week Low$118.05
52-Week Range
$118.05$202.41
$190.68
Fundamentals
Market Cap$28.2B
P/E Ratio20.5
EPS$9.31
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume743K
Avg Volume (10D)—
Shares Outstanding147.6M
About Biogen Inc
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—